Today, Alder BioPharmaceuticals Inc. (ALDR) PT Set at $47.00 by Piper Jaffray Cos.

Today, Alder BioPharmaceuticals Inc. (ALDR) PT Set at $47.00 by Piper Jaffray Cos.

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) has been given a $47.00 target price by stock analysts at Piper Jaffray Cos. in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target points to a potential upside of 75.37% from the stock’s previous close.

ALDR has been the subject of several other reports. Zacks Investment Research downgraded shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 13th. Jefferies Group reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a research note on Tuesday, August 23rd. Aegis initiated coverage on shares of Alder BioPharmaceuticals in a research note on Monday, November 7th. They set a “buy” rating and a $41.00 price objective on the stock. Credit Suisse Group AG reiterated a “buy” rating and set a $38.00 price objective on shares of Alder BioPharmaceuticals in a research note on Tuesday, November 22nd. Finally, Brean Capital initiated coverage on shares of Alder BioPharmaceuticals in a research note on Friday, September 30th. They set a “buy” rating and a $45.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Alder BioPharmaceuticals has an average rating of “Buy” and a consensus target price of $43.38.

Alder BioPharmaceuticals (NASDAQ:ALDR) opened at 23.65 on Friday. The firm has a 50-day moving average of $27.81 and a 200-day moving average of $29.09. Alder BioPharmaceuticals has a 1-year low of $15.82 and a 1-year high of $38.69. The firm’s market capitalization is $1.19 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.15. During the same quarter in the previous year, the company earned ($0.62) earnings per share. On average, analysts expect that Alder BioPharmaceuticals will post ($3.13) earnings per share for the current year.

In related news, VP Jeffrey T. L. Smith sold 3,000 shares of the stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $32.49, for a total value of $97,470.00. Following the sale, the vice president now owns 3,000 shares of the company’s stock, valued at approximately $97,470. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Randall C. Schatzman sold 10,000 shares of the stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $32.48, for a total transaction of $324,800.00. Following the completion of the sale, the insider now directly owns 124,768 shares in the company, valued at approximately $4,052,464.64. The disclosure for this sale can be found here. Company insiders own 11.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ALDR. BlackRock Fund Advisors boosted its stake in Alder BioPharmaceuticals by 4.2% in the first quarter. BlackRock Fund Advisors now owns 1,136,823 shares of the biopharmaceutical company’s stock worth $27,841,000 after buying an additional 45,908 shares during the period. Bank of New York Mellon Corp boosted its stake in Alder BioPharmaceuticals by 85.8% in the second quarter. Bank of New York Mellon Corp now owns 197,768 shares of the biopharmaceutical company’s stock worth $4,938,000 after buying an additional 91,328 shares during the period. Emerald Mutual Fund Advisers Trust purchased a new stake in Alder BioPharmaceuticals during the second quarter worth $5,990,000. Swiss National Bank boosted its stake in Alder BioPharmaceuticals by 72.7% in the second quarter. Swiss National Bank now owns 63,542 shares of the biopharmaceutical company’s stock worth $1,587,000 after buying an additional 26,742 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Alder BioPharmaceuticals by 48.0% in the second quarter. Nationwide Fund Advisors now owns 49,699 shares of the biopharmaceutical company’s stock worth $1,241,000 after buying an additional 16,126 shares during the period.

About Alder BioPharmaceuticals

Related posts

Leave a Comment